Axsome Therapeutics Inc
19X
Company Profile
Business description
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Contact
One World Trade Center
29th Floor
New YorkNY10007
USAT: +1 212 332-3241
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
925
Stocks News & Analysis
stocks
Big 4 earnings: Morningstar analysts form view on impact of slowing housing market
Big 4 bank maintains Fair Value, Short-term earnings not material enough to shift valuation for key player
stocks
ASX healthcare share remains cheap despite mixed earnings result
Shares in Aussie listed healthcare name undervalued post earnings.
stocks
Wide moat ASX share beats earnings guidance
Wide moat share continues to grow despite a challenging residential construction market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,391.10 | 14.40 | -0.15% |
| CAC 40 | 8,714.94 | 11.09 | -0.13% |
| DAX 40 | 26,391.42 | 67.54 | 0.26% |
| Dow JONES (US) | 53,791.85 | 184.13 | -0.34% |
| FTSE 100 | 10,844.19 | 18.31 | -0.17% |
| HKSE | 25,362.91 | 289.91 | -1.13% |
| NASDAQ | 26,445.45 | 159.91 | -0.60% |
| Nikkei 225 | 67,040.18 | 69.96 | 0.10% |
| NZX 50 Index | 13,779.05 | 81.61 | -0.59% |
| S&P 500 | 7,728.20 | 24.91 | -0.32% |
| S&P/ASX 200 | 9,193.00 | 18.60 | -0.20% |
| SSE Composite Index | 3,943.00 | 8.90 | 0.23% |